Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.

ABSTRACT:

Importance

Despite expanded efforts to improve treatment access, inequities exist in the receipt of medications for opioid use disorder by race and ethnicity and insurance type.

Objective

To examine inequities in access to medications for opioid use disorder (MOUD)-specifically buprenorphine and naltrexone-by race and ethnicity and insurance type after opioid-related health care events.

Design, setting, and participants

This retrospective cohort study used data from the Institute for Health Equity Research Multi-Payor Claims Database, which includes more than 130 million individuals across commercial, Medicaid, and Medicare Advantage insurance plans. The cohort consisted of patients aged 18 years or older with an opioid use disorder (OUD)-related health care event (op

SUBMITTER: Khatri UG 

PROVIDER: S-EPMC12203278 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature